Impact of the PI-QUAL MRI quality score on histopathological up-staging from MRI fusion biopsy to final prostatectomy specimen - Top-Institutions - MDSpire

Impact of the PI-QUAL MRI quality score on histopathological up-staging from MRI fusion biopsy to final prostatectomy specimen

  • By

  • Maximilian Haack

  • Mohamad Turkman

  • Tobias Jorg

  • Lukas Müller

  • Gregor Duwe

  • Lisa Johanna Frey

  • Maximilian Peter Brandt

  • Axel Haferkamp

  • Hendrik Borgmann

  • Robert Dotzauer

  • June 30, 2025

  • 0 min

Share

Top Institutions in Urology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Urology
    • Radiology
    • Oncology

  • #2

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Urology
    • Radiology

  • #3

    University College London Hospitals (UCLH)
    University College London Hospitals (UCLH)

    London, N/A

    Key Differentiators

    • Radiology
    • Urology

  • #4

    National Cancer Institute (NCI), NIH
    National Cancer Institute (NCI), NIH

    Bethesda, MD

    Key Differentiators

    • Oncology
    • Radiology
    • Urology

  • #5

    University of Michigan Health System
    University of Michigan Health System

    Ann Arbor, MI

    Key Differentiators

    • Urology
    • Radiology

Original Source(s)

Impact of the PI-QUAL MRI quality score on histopathological up-staging from MRI fusion biopsy to final prostatectomy specimen

  • by Maximilian Haack, Mohamad Turkman, Tobias Jorg, Lukas Müller, Gregor Duwe, Lisa Johanna Frey, Maximilian Peter Brandt, Axel Haferkamp, Hendrik Borgmann, Robert Dotzauer

  • June 30, 2025

Related Content

PHI density prospectively improves prostate cancer detection

Multivariate risk prediction tools including MRI for individualized biopsy decision in prostate cancer diagnosis: current status and future directions

T2 mapping for the characterization of prostate lesions